Western blot analysis showed that Fatostain treatment decreased the expression of HB‐associated genes like AFP, OCT4, GPC3, and DUSP9, indicating that SREBF2 inhibition could reduce hepatoblastoma stemness (Figure S16C, Supporting Information). Here, DUSP9 is linked to hepatoblastoma.